Abstract
PURPOSE OF REVIEW: The importance of the role of histone deacetylase enzymes in the pathogenesis of asthma and chronic respiratory diseases is increasingly being recognized. Similarly, the potential clinical utility of histone deacetylase enzymes in the treatment of disease is emerging. In this review, the role of histone deacetylases (HDAC) and their inhibitors in asthma and chronic obstructive pulmonary disease is discussed.
RECENT FINDINGS: HDAC are able to catalyze the hydrolysis of acetyl groups on lysine residues of histones, causing the condensation and coiling of chromosomal DNA around histones, and therefore regulating gene expression. Histone deacetylase inhibitors act specifically or broadly on HDAC and also on nonhistone targets. Some have been used in the oncology therapeutic field for some years, but it is only more recently that they have been suggested in the treatment of asthma and other inflammatory lung diseases.
SUMMARY: Important developments have been made in the understanding of histone deacetylase expression in normal and diseased airways and pulmonary tissue as well as effects of histone deacetylase inhibitors on structural and inflammatory cells in the lung, including cell proliferation, differentiation and apoptosis and senescence. Many of these discoveries may have implications in addressing airway inflammation, airway remodeling and airway hyperresponsiveness in asthma.
Original language | English |
---|---|
Pages (from-to) | 44-48 |
Number of pages | 5 |
Journal | Current Opinion in Allergy and Clinical Immunology |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - Feb 2014 |
Externally published | Yes |
Keywords
- allergic airways disease
- asthma
- histone deacetylase inhibitor
- inflammatory lung condition
- trichostatin A
Cite this
}
Histone deacetylases and their inhibitors : New implications for asthma and chronic respiratory conditions. / Royce, Simon G.; Karagiannis, Tom C.
In: Current Opinion in Allergy and Clinical Immunology, Vol. 14, No. 1, 02.2014, p. 44-48.Research output: Contribution to journal › Article › Other › peer-review
TY - JOUR
T1 - Histone deacetylases and their inhibitors
T2 - New implications for asthma and chronic respiratory conditions
AU - Royce, Simon G.
AU - Karagiannis, Tom C.
PY - 2014/2
Y1 - 2014/2
N2 - PURPOSE OF REVIEW: The importance of the role of histone deacetylase enzymes in the pathogenesis of asthma and chronic respiratory diseases is increasingly being recognized. Similarly, the potential clinical utility of histone deacetylase enzymes in the treatment of disease is emerging. In this review, the role of histone deacetylases (HDAC) and their inhibitors in asthma and chronic obstructive pulmonary disease is discussed. RECENT FINDINGS: HDAC are able to catalyze the hydrolysis of acetyl groups on lysine residues of histones, causing the condensation and coiling of chromosomal DNA around histones, and therefore regulating gene expression. Histone deacetylase inhibitors act specifically or broadly on HDAC and also on nonhistone targets. Some have been used in the oncology therapeutic field for some years, but it is only more recently that they have been suggested in the treatment of asthma and other inflammatory lung diseases. SUMMARY: Important developments have been made in the understanding of histone deacetylase expression in normal and diseased airways and pulmonary tissue as well as effects of histone deacetylase inhibitors on structural and inflammatory cells in the lung, including cell proliferation, differentiation and apoptosis and senescence. Many of these discoveries may have implications in addressing airway inflammation, airway remodeling and airway hyperresponsiveness in asthma.
AB - PURPOSE OF REVIEW: The importance of the role of histone deacetylase enzymes in the pathogenesis of asthma and chronic respiratory diseases is increasingly being recognized. Similarly, the potential clinical utility of histone deacetylase enzymes in the treatment of disease is emerging. In this review, the role of histone deacetylases (HDAC) and their inhibitors in asthma and chronic obstructive pulmonary disease is discussed. RECENT FINDINGS: HDAC are able to catalyze the hydrolysis of acetyl groups on lysine residues of histones, causing the condensation and coiling of chromosomal DNA around histones, and therefore regulating gene expression. Histone deacetylase inhibitors act specifically or broadly on HDAC and also on nonhistone targets. Some have been used in the oncology therapeutic field for some years, but it is only more recently that they have been suggested in the treatment of asthma and other inflammatory lung diseases. SUMMARY: Important developments have been made in the understanding of histone deacetylase expression in normal and diseased airways and pulmonary tissue as well as effects of histone deacetylase inhibitors on structural and inflammatory cells in the lung, including cell proliferation, differentiation and apoptosis and senescence. Many of these discoveries may have implications in addressing airway inflammation, airway remodeling and airway hyperresponsiveness in asthma.
KW - allergic airways disease
KW - asthma
KW - histone deacetylase inhibitor
KW - inflammatory lung condition
KW - trichostatin A
UR - http://www.scopus.com/inward/record.url?scp=84892363964&partnerID=8YFLogxK
U2 - 10.1097/ACI.0000000000000029
DO - 10.1097/ACI.0000000000000029
M3 - Article
VL - 14
SP - 44
EP - 48
JO - Current Opinion in Allergy and Clinical Immunology
JF - Current Opinion in Allergy and Clinical Immunology
SN - 1528-4050
IS - 1
ER -